http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Merck (MRK) Reports KEYTRUDA Plus Chemotherapy Met Primary Endpoint of Progression-Free Survival (PFS) as First-Line Therapy for Advanced or Recurrent Endometrial Carcinoma
-
Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy Met Primary Endpoint of Progression-Free Survival (PFS) as First-Line Therapy for Advanced or Recurrent Endometrial Carcinoma
-
Merck Announces Fourth-Quarter and Full-Year 2022 Financial Results
-
Merck (MRK) Announces FDA Approval of KEYTRUDA as Adjuvant Treatment Following Surgical Resection and Platinum-Based Chemotherapy for Patients With Stage IB, II, or IIIA (NSCLC)
-
FDA Approves KEYTRUDA® (pembrolizumab) as Adjuvant Treatment Following Surgical Resection and Platinum-Based Chemotherapy for Patients With Stage IB (T2a ≥4 Centimeters), II, or IIIA Non-Small Cell
-
Merck Animal Health Receives U.S. FDA Approval of Expanded Indication for BRAVECTO (fluralaner) Chews for Dogs
-
Merck (MRK) Announces KEYNOTE-991 Trial Evaluating KEYTRUDA Plus Enzalutamide and Androgen Deprivation Therapy
-
Merck Announces KEYNOTE-991 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus Enzalutamide and Androgen Deprivation Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer to Stop for Fut
-
Merck's (MRK) KEYTRUDA Plus Chemotherapy Significantly Improved Overall Survival in KEYNOTE-966 Trial
-
Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy Significantly Improved Overall Survival Versus Chemotherapy in First-Line Advanced or Unresectable Biliary Tract Cancer in KEYNOTE-966 Trial
-
Merck Announces Second-Quarter 2023 Dividend
-
Merck (MRK) completes takeover of Imago BioSciences
-
Merck Completes Tender Offer to Acquire Imago BioSciences, Inc.
-
Merck Named One of America’s Most JUST Companies by JUST Capital and CNBC, Industry Leader in Pharmaceuticals and Biotech
-
Merck to Hold Fourth-Quarter and Full-Year 2022 Sales and Earnings Conference Call February 2
-
Merck to Present at the 41st Annual J.P. Morgan Healthcare Conference
-
Merck to Present at the Goldman Sachs Healthcare CEOs Unscripted Conference
-
Merck (MRK) and Kelun-Biotech Enter Deal for Seven Investigational Antibody-drug Conjugate Cancer Candidates
-
Merck and Kelun-Biotech Announce Exclusive License and Collaboration Agreement for Seven Investigational Antibody-drug Conjugate Candidates for the Treatment of Cancer
-
LYNPARZA® (olaparib) in Combination With Abiraterone and Prednisone or Prednisolone Approved in the EU as Treatment for Certain Patients With Metastatic Castration-Resistant Prostate Cancer
-
Merck (MRK), Seagen (SGEN) and Astellas Announce FDA Acceptance of sBLA for PADCEV with KEYTRUDA
-
Astellas, Seagen and Merck Announce FDA Acceptance of Supplemental Biologics License Applications for PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) for the First-Line Treatment of
-
Seagen, Astellas and Merck Announce FDA Acceptance of sBLAs for PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) for the First-Line Treatment of Certain Patients With Locally Advance
-
AstraZeneca and Merck Provide Update on US Regulatory Review of LYNPARZA® (olaparib) in Combination With Abiraterone and Prednisone or Prednisolone as Treatment of Metastatic Castration-Resistant Pro
-
Merck Begins Tender Offer to Acquire Imago BioSciences, Inc.
-
MilliporeSigma Gains Leading Perfusion Micro-Bioreactor with Erbi Biosystems Acquisition
-
Merck to Present Data From Its Hematology Portfolio and Promising Pipeline at the 64th American Society of Hematology (ASH) Annual Meeting
-
Merck Announces First-Quarter 2023 Dividend
-
Merck (MRK) Announces Phase 3 KEYNOTE-859 Trial Met Primary Endpoint
-
Merck Announces Phase 3 KEYNOTE-859 Trial Met Primary Endpoint of Overall Survival in Patients With HER2-Negative Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
-
Disney, Imago BioSciences rise premarket; Coinbase, Carvana fall
-
Merck (MRK) Acquires Imago BioSciences (IMGO) for $36/sh or $1.35B
-
Merck to Present at the 5th Annual Evercore ISI HealthCONx Conference
-
Merck to Acquire Imago BioSciences, Inc.
-
MilliporeSigma Invests $ 286 Million in U.S. Drug Safety Testing Capacity
-
Merck's (MRK) LYNPARZA in Combination With Abiraterone and Prednisone or Prednisolone Recommended for Approval in EU
-
LYNPARZA® (olaparib) in Combination With Abiraterone and Prednisone or Prednisolone Receives Positive Opinion From EU CHMP as Treatment for Certain Patients With Metastatic Castration-Resistant Prost
-
Portage Biotech (PRTG) Announces Clinical Trial Collaboration Agreement with Merck (MRK)
-
Reductions in Certain Types of HPV-Related Cervical and Non-Cervical Diseases in Women and Men Observed with Real-World Use of Merck's GARDASIL® in Systematic Literature Review of 138 Studies
-
Veeva Systems (VEEV) and Merck (MRK) Enter Long-Term Strategic Partnership
-
Veeva and Merck Form Long-Term Strategic Partnership
-
Merck Announces Third-Quarter 2022 Financial Results
-
Merck (MRK) Announces Robert M. Davis to Succeed Kenneth C. Frazier as Chairman
-
Robert M. Davis to Succeed Kenneth C. Frazier as Chairman of Merck
-
Merck (MRK) Granted Expanded EU VAXNEUVANCE Indication to Include Infants, Children and Adolescents
-
European Commission Expands Merck’s VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) Indication to Include Infants, Children and Adolescents
-
Merck (MRK) Reports Positive Phase 3 Data of PREVYMIS for Prevention of Cytomegalovirus Disease
-
Merck’s PREVYMIS™ Demonstrates Efficacy in Phase 3 Study for Prevention of Cytomegalovirus Disease in Adults After Kidney Transplantation
-
Merck Animal Health Launches Sure Petcare Animo® GPS
-
Merck and the Bill & Melinda Gates Medical Research Institute Announce Licensing Agreement for Novel Tuberculosis Antibiotic Candidates
